Recombinant Anti-B7H6 x Anti-CD3 Bispecific Antibody (Fv-IgG) (BSDG-017)

Recombinant Anti-B7H6 x Anti-CD3 Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-B7H6 IgG with similar domains from an anti-CD3 antibody via short peptide linkers, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Hematologic neoplasms; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

B7H6 & CD3

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Hematologic neoplasms; Solid tumors

Targets

Target 1

B7H6

Gene ID

374383

UniProt ID

Q68D85

Alternative Names

NCR3LG1; natural killer cell cytotoxicity receptor 3 ligand 1; B7H6; B7-H6; DKFZp686O24166; natural cytotoxicity triggering receptor 3 ligand 1; B7 homolog 6; putative Ig-like domain-containing protein DKFZp686O24166/DKFZp686I21167

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-B7H6 x Anti-CD3 Bispecific Antibody (Fv-IgG) (BSDG-017). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-B7H6 x Anti-CD3 Bispecific Antibody (Fv-IgG) (CAT#: BSDG-017)

Specifications

Targets

Customer Reviews and Q&As